NCT05342558View on ClinicalTrials.gov

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

PHASE4CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

November 19, 2020

Study Completion Date

February 1, 2021

Conditions
COPD
Interventions
DRUG

Fluticasone Furoate/Vilanterol 100/25 mcgs

Dry powder inhaler with 30 blisters. 100/25mcgs a day for 24 weeks.

DRUG

Umeclidinium/Vilanterol 62.5/25 mcgs

Dry powder inhaler with 30 blisters. 62.5/25mcgs a day for 24 weeks

Trial Locations (1)

14080

National Institute of Respiratory Diseases 'Ismael Cosío Villegas', Mexico City

All Listed Sponsors
lead

National Institute of Respiratory Diseases, Mexico

OTHER_GOV

NCT05342558 - Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes. | Biotech Hunter | Biotech Hunter